Clinical Trials Logo

Filter by:
NCT ID: NCT06170450 Recruiting - Clinical trials for Overactive Bladder Syndrome

Cyclic Versus Continuous Sacral Neuromodulation for LUTS

Start date: April 15, 2024
Phase: N/A
Study type: Interventional

This will be a prospective, randomized-controlled multi-site trial comparing cyclic versus continuous sacral neuromodulation (SNM) for OAB.

NCT ID: NCT06170437 Not yet recruiting - Tobacco Smoking Clinical Trials

Smoke-free Home Study in Subsidized Housing

Start date: August 1, 2024
Phase: N/A
Study type: Interventional

Comprehensive smoke-free policies have the potential to substantially reduce tobacco-related disparities among populations in subsidized housing. This study fills this gap by identifying approaches to increase the implementation of smoke-free policies in all types of subsidized housing by increasing the voluntary adoption of smoke-free homes and promoting access to smoking cessation services.

NCT ID: NCT06170281 Recruiting - Migraine Clinical Trials

Sequential, Multiple Assignment, Double Randomized Preference, Migraine Behavioral Trial

SMARTMig
Start date: December 15, 2023
Phase: N/A
Study type: Interventional

This study will unpack the behavioral intervention for migraine and determine the optimum combinations. In addition, the study will test preference and self-selection effects during the trial.

NCT ID: NCT06170268 Recruiting - Alzheimer Disease Clinical Trials

Alzheimer's National Registry for Treatment and Diagnostics(ALZ-NET)

ALZ-NET
Start date: October 20, 2022
Phase:
Study type: Observational [Patient Registry]

The Alzheimer's Network for Treatment and Diagnostics (ALZ-NET) will collect longitudinal clinical and safety data for enrolled patients being evaluated for or treated with novel FDA-approved Alzheimer's disease (AD) therapies. ALZ-NET is a longitudinal registry with an expandable platform, designed to grow with scientific and medical advancements. As new treatments are approved and implemented in care, ALZ-NET will track the long-term health outcomes associated with their use in a real-world setting. ALZ-NET is a resource for evidence gathering, information sharing and education across clinical and research communities, encouraging innovative research and supporting opportunities to improve clinical care delivery. All participating physicians and site staff will complete comprehensive training to ensure adherence of data requirements and registry timelines.

NCT ID: NCT06170047 Enrolling by invitation - Parenting Clinical Trials

Chicago Parent Program for Foster and Kinship Caregivers

Start date: February 2, 2024
Phase: N/A
Study type: Interventional

The primary objective of this study is to test the effects of an evidence-based prevention intervention (CPP) adapted for foster and kinship caregivers of young children (FC; foster care) on caregiver competence and child behavior problems for children in foster care compared with an active comparator group that receives standard supports through the child welfare and healthcare systems (i.e., usual care).

NCT ID: NCT06169852 Recruiting - Parkinson Disease Clinical Trials

Stimulus-Evoked Directional Field Potentials to Guide Subthalamic and Pallidal DBS for PD

Start date: January 12, 2024
Phase: N/A
Study type: Interventional

The purpose of the study is to determine whether new deep brain stimulation (DBS) device technologies can generate and record brain rhythms to reveal the best location for clinical stimulation.

NCT ID: NCT06169826 Not yet recruiting - Alzheimer Disease Clinical Trials

Histidine Oral Supplementation as a Therapeutic Modality for Alzheimer's Disease

Start date: June 2024
Phase: Phase 4
Study type: Interventional

Oral supplementation of histidine in patients with cognitive dysfunction should increase brain anserine, carnosine and histamine levels which will result in improved cognition via numerous proven in vivo mechanisms including increasing blood flow, neurogenesis, angiogenesis, activation of histaminergic neural pathways and autophagy of beta-amyloid protein, which is pathognomonic for Alzheimer's disease. Randomized into one of 2 arms to receive Histidine or placebo to take for up to 3 months. Baseline evaluation and followup evaluation at 3 months postop.

NCT ID: NCT06169774 Recruiting - Intestinal Failure Clinical Trials

Video Training Supplementation for Patients Discharged on Home Parental Nutrition

Start date: January 1, 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to develop an educational video addressing the aseptic techniques to safely handle central catheters for administrating parenteral nutrition at home.

NCT ID: NCT06169735 Recruiting - Adenoma Clinical Trials

Does Fluorescence With or Without Indocyanine Green Improve Parathyroid Identification and Preservation

Start date: April 11, 2024
Phase: Phase 4
Study type: Interventional

The aim of this study is to determine if fluorescence with or without indocyanine green can facilitate safe and accurate thyroid and parathyroid surgery.

NCT ID: NCT06169696 Not yet recruiting - Clinical trials for Spinal Cord Injuries

EMPOWER Early Feasibility Study: Non-invasive BCI to Control a Wheelchair for People With Paralysis

Start date: November 2024
Phase: N/A
Study type: Interventional

Neuralis is an innovative assistive technology designed for individuals with severe neuromuscular conditions, enabling wheelchair control through EEG signals. This study aims to assess the safety, feasibility, and efficacy of Neuralis in restoring mobility and independence. The device is a discreet EEG headset which specializes in decoding signals from visual cortex, allowing users to initiate precise wheelchair movements through focused attention. This research seeks to demonstrate Neuralis' potential in revolutionizing assistive technology by offering a non-invasive, user-friendly solution for individuals facing motor impairments, ultimately enhancing their quality of life.